Reducing central line-associated bloodstream infections in pediatric intestinal failure
"Children with IF who were treated with rifaximin experienced fewer CLABSI events, suggesting that rifaximin is a viable option for CLABSI prophylaxis in pediatric IF patients" Johnson et al (2026).